SG11202003687RA - Methods of using and compositions containing dulaglutide - Google Patents

Methods of using and compositions containing dulaglutide

Info

Publication number
SG11202003687RA
SG11202003687RA SG11202003687RA SG11202003687RA SG11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA SG 11202003687R A SG11202003687R A SG 11202003687RA
Authority
SG
Singapore
Prior art keywords
methods
compositions containing
dulaglutide
containing dulaglutide
compositions
Prior art date
Application number
SG11202003687RA
Other languages
English (en)
Inventor
David Andrew Cox
Zvonko Milicevic
Lai San Tham
Andrew Gordon Werner
David Bradley Woodward
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202003687RA publication Critical patent/SG11202003687RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11202003687RA 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide SG11202003687RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (fr) 2017-11-21 2018-11-13 Procédés d'utilisation et compositions contenant du dulaglutide

Publications (1)

Publication Number Publication Date
SG11202003687RA true SG11202003687RA (en) 2020-06-29

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003687RA SG11202003687RA (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Country Status (20)

Country Link
US (1) US11576950B2 (fr)
EP (1) EP3713593A2 (fr)
JP (3) JP7221956B2 (fr)
KR (2) KR102589234B1 (fr)
CN (1) CN111356472A (fr)
AU (2) AU2018372709B2 (fr)
BR (1) BR112020007817A2 (fr)
CA (1) CA3082625A1 (fr)
CL (1) CL2020001252A1 (fr)
CR (1) CR20200202A (fr)
DO (1) DOP2020000104A (fr)
EA (1) EA202090971A1 (fr)
EC (1) ECSP20026436A (fr)
IL (1) IL274563B2 (fr)
JO (1) JOP20200126A1 (fr)
MA (1) MA50798A (fr)
MX (1) MX2020005231A (fr)
SG (1) SG11202003687RA (fr)
UA (1) UA127588C2 (fr)
WO (1) WO2019103875A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1724284T3 (da) 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
WO2005000892A2 (fr) 2003-06-12 2005-01-06 Eli Lilly And Company Proteines hybrides analogues de glp-1
WO2006068910A1 (fr) 2004-12-22 2006-06-29 Eli Lilly And Company Preparations contenant une proteine hybride analogue du glp-1
AU2008275180A1 (en) * 2007-07-10 2009-01-15 Eli Lilly And Company GLP-1-Fc fusion protein formulation
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (fr) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Thérapies pour l'obésité, le diabète et indications associées
US20200171129A1 (en) 2017-06-01 2020-06-04 Eli Lilly And Company Therapeutic uses of dulaglutide

Also Published As

Publication number Publication date
JP7221956B2 (ja) 2023-02-14
JOP20200126A1 (ar) 2020-05-21
MX2020005231A (es) 2020-08-24
AU2022203372A1 (en) 2022-06-09
CL2020001252A1 (es) 2020-10-30
BR112020007817A2 (pt) 2020-10-06
IL274563B1 (en) 2023-08-01
IL274563A (en) 2020-06-30
KR20200076705A (ko) 2020-06-29
JP2021502379A (ja) 2021-01-28
JP2022062153A (ja) 2022-04-19
DOP2020000104A (es) 2020-08-31
MA50798A (fr) 2020-09-30
CA3082625A1 (fr) 2019-05-31
WO2019103875A3 (fr) 2019-07-25
JP2024056908A (ja) 2024-04-23
WO2019103875A2 (fr) 2019-05-31
US20200330558A1 (en) 2020-10-22
AU2018372709A1 (en) 2020-05-14
ECSP20026436A (es) 2020-06-30
IL274563B2 (en) 2023-12-01
EP3713593A2 (fr) 2020-09-30
AU2018372709B2 (en) 2022-04-28
US11576950B2 (en) 2023-02-14
EA202090971A1 (ru) 2020-08-07
KR102589234B1 (ko) 2023-10-16
CR20200202A (es) 2020-08-20
UA127588C2 (uk) 2023-10-25
CN111356472A (zh) 2020-06-30
KR20220146656A (ko) 2022-11-01
NZ763815A (en) 2023-11-24

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
HK1256726A1 (zh) 載體結合劑組合物及其製備和使用方法
EP3576782A4 (fr) Compositions de produit de recombinaison-peptide et leurs méthodes d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
HK1248531A1 (zh) 免疫調節組合物及其使用方法
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
ZA201906169B (en) Synthekine compositions and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Preparations and methods of use
HK1251979A1 (zh) 肽組合物和使用方法
ZA202004531B (en) Compositions containing thymohydroquinone and their method of preparation
IL275739A (en) Preparations for cryopreservation and methods of their use
HK1250345A1 (zh) 包含15-氧代-epa或15-氧代-dgla的組合物及其製備和使用方法
HK1252057A1 (zh) 新穎的使用方法和組合物
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
ZA202000502B (en) Cosmetic compositions and methods of use
IL282533A (en) Oligosaccharide preparations and methods of using them
GB201621737D0 (en) Compositions and methods of treatment
EP3253396A4 (fr) Compositions probiotiques et procédés d'utilisation
HK1248527A1 (zh) 牙科組合物和使用方法
IL274563A (en) Methods of use and preparations containing dolaglutide
IL261794A (en) Preparations and methods for using them
GB201810925D0 (en) Compositions and methods of treatment
GB201710491D0 (en) Composition and methods of treatment